### ORBIT TECHNOLOGIES LTD.

### CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

### **AS OF MARCH 31, 2023**

### **UNAUDITED**

### U.S. DOLLARS IN THOUSANDS

### **INDEX**

	Page
Consolidated Balance Sheets	3 - 2
Consolidated Statements of Income	4
Consolidated Statements of Comprehensive Income	5
Consolidated Statements of Changes in Equity	7 - 6
Consolidated Statements of Cash Flows	9 - 8
Note to Consolidated financial Statements	10

----

	Marc	December 31,		
	2023	2022	2022	
	Unaud	dited	Audited	
	U.S.	usands		
ASSETS				
CURRENT ASSETS:				
Cash and cash equivalents	18,936	28,177	21,746	
Short term deposit	12,990	-	12,815	
Accounts receivables	10,132	8,655	11,615	
Amounts due for construction contracts	19,017	7,810	16,620	
Other accounts receivable	1,852	1,679	2,731	
Inventories	11,026	6,992	9,528	
	73,953	53,313	75,055	
NON-CURRENT ASSETS:				
Other assets	10	10	10	
Fixed assets	18,902	14,606	18,248	
Intangible assets	12,691	9,203	11,809	
Goodwill	785	785	785	
Deferred taxes	212	883	217	
	32,600	25,487	31,069	
	106,553	78,800	106,124	

Date of approval of the

financial statements

<b>March 31</b> ,		December 31,
2023	2022	2022
		Audited
<b>U.S.</b>	dollars in thou	ısands
9,060	6,710	11,032
313	-	258
13,950	14,883	13,309
23,323	21,593	24,599
530	532	518
209	440	212
9,475	9,066	9,925
744	684	713
454	871	467
518	497	349
11,930	12,090	12,184
8,198	6,497	8,196
36618	21,071	36,603
-	1,761	-
25,094	15,103	23,373
2,073	1,321	1,907
	(420)	(592)
		721
(867)	(867)	(867)
71,300	45,117	69,341
106,553		
	9,060 313 13,950 23,323  530 209 9,475 744 454 518  11,930  8,198 36618  25,094 2,073 (537) 721 (867)	Unaudited       U.S. dollars in thou       9,060     6,710       313     -       13,950     14,883       23,323     21,593       530     532       209     440       9,475     9,066       744     684       454     871       518     497       11,930     12,090       8,198     6,497       36618     21,071       -     1,761       25,094     15,103       2,073     1,321       (537)     (420)       721     651       (867)     (867)

D. Eshchar

CEO

R. Wirth

CFO

Yitzchak Gat

Chairman of the Board

# CONSOLIDATED STATEMENTS OF INCOME

	Three montl March	Year ended December 31,			
	2023	2022	2022		
	Unaudi	ted	Audited		
	U.S. o	lollars in thou	ousands		
	(exce	e data)			
Revenues from sales and construction performed	13,478	12,501	59,006		
Cost of sales and construction performed	8,849	7,776	37,177		
Gross profit	4,629	4,725	21,829		
Research and development costs, net	515	618	3,531		
Selling and marketing expenses	1,365	1,344	5,216		
General and administrative expenses	997	1,059	3,788		
Operating income before other expenses	1,752	1,704	9,294		
Other expenses		231	271		
Operating income after other expenses	1,752	1,473	9,023		
Finance income	468	300	2,501		
Finance expenses	202	77	349		
Income before taxes on income	2,018	1,696	11,175		
Income tax expense	297	289	1,498		
Net Profit	1,721	1,407	9,677		
Net Profit per share attributable to equity holders of the Company (in U.S. dollars):					
Basic profit per share	0.070	0.076	0.493		
Diluted profit per share	0.069	0.062	0.426		

# CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

	Three mon Marc	Year ended December 31,		
	2023	2022	2022	
	Unaud	lited	Audited	
	U.S.	dollars in thou	ısands	
Net Profit	1,721	1,407	9,677	
Other comprehensive profit (net of tax effect):				
Actuarial loss from defined benefit plans Foreign currency translation adjustments of foreign	-	-	70	
operation	55	(62)	(234)	
Total other comprehensive income (loss)	55	(62)	(164)	
Total comprehensive income	1,776	1,345	9,513	

### CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

	Share capital	Paid-in capital	Warrants	Retained earnings	Reserve for share-based payment U.S. dollars		Reserve for defined benefit plans	Treasury shares	Total equity
					Unaudite	ed			
Balance at January 1, 2023 (audited)	8,196	36,603	-	23,373	1,907	(592)	- 721	(867)	69,341
Net Income	-	-	-	1,721	-	-	-	-	1,721
Other comprehensive loss				-		55			55
Total comprehensive income	-	-	-	1,721		55			1,776
Exercise of warrants into shares	2	15	-	-	(8)	-	-	-	9
Cost of share based-payment				-	174				174
Balance at March 31, 2023	8,198	36,618	-	25,094	2,073	(537)	721	(867)	71,300
	Share	Paid-in	YY.	Retained .	Reserve for share-based	Foreign currency translation	Reserve for defined benefit	Treasury	Total
	<u>capital</u>	capital	Warrants	earnings	payment U.S. dollars	adjustments	plans	shares	equity
					U.S. donars I				
Balance at January 1, 2022 (audited)	6,493	21,039	1,761	13,696	1,118	(358)	651	(867)	43,533
Net Income	-	_	-	1,407	-	-	-	-	1,407
Other comprehensive loss				-		(62)	<u>-</u> _		(62)
Total comprehensive income (loss)	-	-	-	1,407	-	(62)			1,345
Exercise of warrants into shares	4	32	-	-	(32)	-	-	-	4
Cost of share based-payment				-	235				235

The accompanying note is an integral part of the interim consolidated financial statements.

Balance at March 31, 2022

15,103

1,321

(420)

### CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

	Share capital	Paid-in capital	Warrants	Retained earnings	Reserve for share-based payment U.S. dollars	Foreign currency translation adjustments in thousands	Reserve for defined benefit plans	Treasury shares	Total equity
					Audited	ì			
Balance at December 31, 2021	6,493	21,039	1,761	13,696	1,118	(358)	651	(867)	43,533
Net Income	-	-	-	9,677	-	-	-	-	9, 677
Other comprehensive loss	-	-	-	-	-	(234)	_	-	(164)
Total comprehensive income (loss)	_	_	-	9,677		(234)			9,513
Exercise of warrants into shares by controlling shareholder	1,681	15,335	(1,761)	-	-	-	_	-	15,255
Forfeiture of options	23	229	-	-	(75)				177
Cost of share based-payment				-	863				863
Balance at December 31, 2022	8,196	36,603		23,373	1,907	(592)	- 721	(867)	69,341

# CONSOLIDATED STATEMENTS OF CASH FLOWS

	Three mont	Year ended December 31,	
<del>-</del>	2023	2022	2022
_	Unaudited		Audited
_	U.S.	ısands	
Cash flows from operating activities:			
Net income	1,721	1,407	9,677
Adjustments to reconcile net income to net cash provided by operating activities:			
Adjustments to the profit or loss items:			
Depreciation and amortization	770	779	3,227
Capital Gain from sale of fixed assets	-	-	57
Cost of share-based payment	174	235	863
Tax expense	297	289	1,498
Interest expenses, net	(106)	68	90
Change in employee benefit Liability, net	(2)	(7)	(173)
Adjustment to current accounts with foreign operation	30	(32)	(323)
	1,163	1,332	5,239
Changes in operating asset and liability items:			
Decrease in trade receivables	1,483	3,166	206
Increase in amounts due for construction contracts	(2,396)	(756)	(9,566)
Increase in other accounts receivable	(226)	(167)	(125)
increase in inventories	(1,523)	(507)	(3,239)
Increase (Decrease) in trade payables	(1,359)	(1,043)	2,748
Increase (Decrease) in other accounts payable	378	(1,736)	(4,406)
	(3,643)	(1,043)	(14,382)
Cash paid and received during the period for:			
Interest paid	(201)	(77)	(349)
Interest received	308	9	259
Taxes paid	(11)	(37)	(307)
<u>-</u>	96	(105)	(397)
Net cash provided by (Used in) operating activities	(663)	1,591	137

# CONSOLIDATED STATEMENTS OF CASH FLOWS

2023 2022         2022           Unaudled         Audited           Unaverse of fixed assets           Cash flows from investing activities:           Purchase of fixed assets         (666)         (228)         (3,757)           Capitalization of research and development costs         (1,026)         (1,382)         (4,434)           Net ash used to activity acquisition         -         (1,692)         (2,862)         (22,330)           Deposit in banking corporations         (1,692)         (2,862)         (22,330)           Net Used in investing activities         (1,692)         (2,862)         (22,330)           Payments for Government grants         -         -         -         (5)           Payments of lease liability         (434)         (473)         (1,696)           Exercise of warrants into shares by controlling shareholder         -         -         -         15,255           Exercise of warrants into shares         9         4         177           Net cash provided by (Used in) financing activities         (425)         (469)         13,731           Translation differences on balances of cash and cash equivalents         (2,810)         (1,708)         (8,139)           Cash and		Three mont March	Year ended December 31,		
Cash flows from investing activities:           Purchase of fixed assets         (666)         (228)         (3,757)           Capitalization of research and development costs         (1,026)         (1,282)         (4,434)           Net cash used to activity acquisition         -         (1,352)         (13,52)           Deposit in banking corporations         -         -         (12,787)           Net Used in investing activities         (1,692)         (2,862)         (22,330)           Cash flows from financing activities:         -         -         (5)           Payments for Government grants         -         -         -         (5)           Payments of lease liability         (434)         (473)         (1,696)           Exercise of warrants into shares by controlling shareholder         -         -         15,255           Exercise of warrants into shares         9         4         177           Net cash provided by (Used in) financing activities         (425)         (469)         13,731           Translation differences on balances of cash and cash equivalents         (2,810)         (1,708)         (8,139)           Decrease in cash and cash equivalents at the beginning of the period         21,746         29,885         29,885           Cash and cash e		2023	2022		
Cash flows from investing activities:           Purchase of fixed assets         (666)         (228)         (3,757)           Capitalization of research and development costs         (1,026)         (1,282)         (4,434)           Net cash used to activity acquisition         -         (1,352)         (13,52)           Deposit in banking corporations         -         -         (12,787)           Net Used in investing activities         (1,692)         (2,862)         (22,330)           Cash flows from financing activities:         -         -         (5)           Payments for Government grants         -         -         -         (5)           Payments of lease liability         (434)         (473)         (1,696)           Exercise of warrants into shares by controlling shareholder         -         -         -         15,255           Exercise of warrants into shares         9         4         177           Net cash provided by (Used in) financing activities         (425)         (469)         13,731           Translation differences on balances of cash and cash equivalents         (2,810)         (1,708)         (8,139)           Cash and cash equivalents at the beginning of the period         21,746         29,885         29,885           Cash and		Unaud	ited	Audited	
Purchase of fixed assets         (666)         (228)         (3,757)           Capitalization of research and development costs         (1,026)         (1,282)         (4,434)           Net cash used to activity acquisition         -         (1,352)         (1,352)           Deposit in banking corporations         -         -         (12,787)           Net Used in investing activities         (1,692)         (2,862)         (22,330)           Cash flows from financing activities:         -         -         (5)           Payments for Government grants         -         -         -         (5)           Payments of lease liability         (434)         (473)         (1,696)           Exercise of warrants into shares by controlling shareholder         -         -         -         15,255           Exercise of warrants into shares         9         4         177           Net cash provided by (Used in) financing activities         (425)         (469)         13,731           Translation differences on balances of cash and cash equivalents         (2,810)         (1,708)         (8,139)           Decrease in cash and cash equivalents at the beginning of the period         21,746         29,885         29,885           Cash and cash equivalents at the end of the period         18,936		U.S. 0	dollars in thou	usands	
Capitalization of research and development costs         (1,026)         (1,282)         (4,434)           Net cash used to activity acquisition         -         (1,352)         (1,352)           Deposit in banking corporations         -         -         (12,787)           Net Used in investing activities         (1,692)         (2,862)         (22,330)           Cash flows from financing activities:         -         -         (5)           Payments for Government grants         -         -         -         (5)           Payments of lease liability         (434)         (473)         (1,696)           Exercise of warrants into shares by controlling shareholder         -         -         -         15,255           Exercise of warrants into shares         9         4         177           Net cash provided by (Used in) financing activities         (425)         (469)         13,731           Translation differences on balances of cash and cash equivalents         (2,810)         (1,708)         (8,139)           Decrease in cash and cash equivalents at the beginning of the period         21,746         29,885         29,885           Cash and cash equivalents at the end of the period         18,936         28,177         21,746           Significant non-cash transaction: <t< th=""><th>Cash flows from investing activities:</th><th></th><th></th><th></th></t<>	Cash flows from investing activities:				
Net cash used to activity acquisition Deposit in banking corporations  Cash flows from financing activities:  Payments for Government grants Payments of lease liability Exercise of warrants into shares by controlling shareholder Exercise of warrants into shares  Pexercise of warrants into shares  Pexercise of warrants into shares  Security acquisition  Cash flows from financing activities:  Payments for Government grants  (5) Payments of lease liability (434) (473) (1,696)  Exercise of warrants into shares by controlling shareholder  15,255  Exercise of warrants into shares  9	Purchase of fixed assets	(666)	(228)	(3,757)	
Deposit in banking corporations         -         -         (12,787)           Net Used in investing activities         (1,692)         (2,862)         (22,330)           Cash flows from financing activities:         -         -         (5)           Payments for Government grants         -         -         -         (5)           Payments of lease liability         (434)         (473)         (1,696)           Exercise of warrants into shares by controlling shareholder         -         -         -         15,255           Exercise of warrants into shares         9         4         177           Net cash provided by (Used in) financing activities         (425)         (469)         13,731           Translation differences on balances of cash and cash equivalents         (30)         32         323           Decrease in cash and cash equivalents         (2,810)         (1,708)         (8,139)           Cash and cash equivalents at the beginning of the period         21,746         29,885         29,885           Cash and cash equivalents at the end of the period         18,936         28,177         21,746           Significant non-cash transaction:         276         359         890	Capitalization of research and development costs	(1,026)	(1,282)	(4,434)	
Net Used in investing activities (1,692) (2,862) (22,330)  Cash flows from financing activities:  Payments for Government grants (5) Payments of lease liability (434) (473) (1,696) Exercise of warrants into shares by controlling shareholder - 15,255 Exercise of warrants into shares 9 4 177  Net cash provided by (Used in) financing activities (425) (469) 13,731  Translation differences on balances of cash and cash equivalents (2,810) (1,708) (8,139)  Cash and cash equivalents at the beginning of the period 21,746 29,885 29,885  Cash and cash equivalents at the end of the period 18,936 28,177 21,746  Significant non-cash transaction:  Purchase of fixed assets on suppliers credit 276 359 890	Net cash used to activity acquisition	-	(1,352)	(1,352)	
Cash flows from financing activities:  Payments for Government grants (5) Payments of lease liability (434) (473) (1,696) Exercise of warrants into shares by controlling shareholder - 15,255 Exercise of warrants into shares 9 4 177  Net cash provided by (Used in) financing activities (425) (469) 13,731  Translation differences on balances of cash and cash equivalents (30) 32 323  Decrease in cash and cash equivalents (2,810) (1,708) (8,139)  Cash and cash equivalents at the beginning of the period 21,746 29,885 29,885  Cash and cash equivalents at the end of the period 18,936 28,177 21,746  Significant non-cash transaction:  Purchase of fixed assets on suppliers credit 276 359 890	Deposit in banking corporations			(12,787)	
Payments for Government grants Payments of lease liability Payments of lease liability Exercise of warrants into shares by controlling shareholder Starcise of warrants into shares Payments of lease liability Exercise of warrants into shares by controlling shareholder Payments of lease liability Exercise of warrants into shares Payments of lease liability Exercise of warrants into shares Payments	Net Used in investing activities	(1,692)	(2,862)	(22,330)	
Payments of lease liability  Exercise of warrants into shares by controlling shareholder  Exercise of warrants into shares  9	Cash flows from financing activities:				
Exercise of warrants into shares by controlling shareholder  Exercise of warrants into shares  9	Payments for Government grants	-	-	(5)	
Shareholder Exercise of warrants into shares  Purchase of fixed assets on suppliers credit  Exercise of warrants into shares  15,255 177 177 187 187 187 187 187 187 187 187	Payments of lease liability	(434)	(473)	(1,696)	
Exercise of warrants into shares 9 4 177  Net cash provided by (Used in) financing activities (425) (469) 13,731  Translation differences on balances of cash and cash equivalents (30) 32 323  Decrease in cash and cash equivalents (2,810) (1,708) (8,139)  Cash and cash equivalents at the beginning of the period 21,746 29,885 29,885  Cash and cash equivalents at the end of the period 18,936 28,177 21,746  Significant non-cash transaction:  Purchase of fixed assets on suppliers credit 276 359 890					
Net cash provided by (Used in) financing activities (425) (469) 13,731  Translation differences on balances of cash and cash equivalents (30) 32 323  Decrease in cash and cash equivalents (2,810) (1,708) (8,139)  Cash and cash equivalents at the beginning of the period 21,746 29,885 29,885  Cash and cash equivalents at the end of the period 18,936 28,177 21,746  Significant non-cash transaction:  Purchase of fixed assets on suppliers credit 276 359 890		-	-	-	
Translation differences on balances of cash and cash equivalents  (30) 32 323  Decrease in cash and cash equivalents  (2,810) (1,708) (8,139)  Cash and cash equivalents at the beginning of the period 21,746 29,885 29,885  Cash and cash equivalents at the end of the period 18,936 28,177 21,746  Significant non-cash transaction:  Purchase of fixed assets on suppliers credit 276 359 890	Exercise of warrants into shares	9	4	177	
equivalents (30) 32 323  Decrease in cash and cash equivalents (2,810) (1,708) (8,139)  Cash and cash equivalents at the beginning of the period 21,746 29,885 29,885  Cash and cash equivalents at the end of the period 18,936 28,177 21,746  Significant non-cash transaction:  Purchase of fixed assets on suppliers credit 276 359 890	Net cash provided by (Used in) financing activities	(425)	(469)	13,731	
equivalents (30) 32 323  Decrease in cash and cash equivalents (2,810) (1,708) (8,139)  Cash and cash equivalents at the beginning of the period 21,746 29,885 29,885  Cash and cash equivalents at the end of the period 18,936 28,177 21,746  Significant non-cash transaction:  Purchase of fixed assets on suppliers credit 276 359 890	Translation differences on balances of cash and cash				
Cash and cash equivalents at the beginning of the period 21,746 29,885 29,885  Cash and cash equivalents at the end of the period 18,936 28,177 21,746  Significant non-cash transaction:  Purchase of fixed assets on suppliers credit 276 359 890		(30)	32	323	
Cash and cash equivalents at the beginning of the period 21,746 29,885 29,885  Cash and cash equivalents at the end of the period 18,936 28,177 21,746  Significant non-cash transaction:  Purchase of fixed assets on suppliers credit 276 359 890	Decrease in cash and cash equivalents	(2,810)	(1,708)	(8,139)	
Cash and cash equivalents at the end of the period 18,936 28,177 21,746  Significant non-cash transaction:  Purchase of fixed assets on suppliers credit 276 359 890	•		, , ,		
Significant non-cash transaction:  Purchase of fixed assets on suppliers credit 276 359 890	Cash and cash equivalents at the beginning of the period	21,746	29,885	29,885	
Purchase of fixed assets on suppliers credit 276 359 890	Cash and cash equivalents at the end of the period	18,936	28,177	21,746	
	Significant non-cash transaction:				
	Purchase of fixed assets on suppliers credit	276	359	890	

#### **NOTE 1:- GENERAL**

These financial statements have been prepared in a condensed format as of March 31, 2023 and for the three months then ended ("interim financial statements"). These financial statements should be read in conjunction with the Company's annual financial statements as of December 31, 2022 and for the year then ended and accompanying notes ("annual financial statements").